Cumberland Pharmaceuticals Inc. — FY2020 Form 10-K Summary
Business context and reporting period
Cumberland is a specialty pharmaceutical company focused on branded prescription products for hospital acute care, gastroenterology and rheumatology. Its portfolio includes Acetadote, Caldolor, Kristalose, Omeclamox-Pak, Vaprisol, Vibativ and RediTrex, supported by U.S. hospital and field sales forces and international partners.
The filing covers the fiscal year ended December 31, 2020. Fourth-quarter 2020 net revenue was $10.3 million, operating loss was $1.7 million, continuing-operations net loss was $1.8 million and net loss attributable to common shareholders was $0.9 million.
Financial performance and key metrics
| Metric | 2020 | 2019 | Change |
|---|---|---|---|
| Net revenues | $37.4 million | $34.4 million | Up 8.9% |
| Cost of products sold | $8.7 million | $7.4 million | Up $1.2 million |
| Gross profit | $28.8 million | $27.0 million | Gross margin declined to 76.9% from 78.4% |
| Operating loss | $6.4 million | $9.3 million | Improved by $2.9 million |
| Net loss from continuing operations | $6.6 million | $9.2 million | Improved by $2.6 million |
| Net loss attributable to common shareholders | $3.3 million | $3.5 million | Improved by $0.2 million |
| Basic and diluted loss per share | $(0.22) | $(0.23) | Improved by $0.01 |
| Cash flow from operations | $5.4 million | $3.1 million | Up $2.4 million |
- Continuing-operations operating margin was approximately negative 17.0%; continuing-operations net margin was approximately negative 17.7%.
- Product revenue was $35.8 million, while other revenue was $1.6 million, including grant, licensing and other activities.
- Leading products were Kristalose at $15.6 million and Vibativ at $10.9 million. Caldolor generated $5.3 million, Acetadote $1.9 million, Vaprisol $1.1 million, RediTrex $0.9 million and Omeclamox-Pak $0.3 million.
- Cash and cash equivalents were $24.8 million at year-end, down from $28.2 million. Working capital was $24.3 million, with a current ratio of 1.9.
- Debt included $15.0 million outstanding under the revolving credit facility and $2.2 million under the Paycheck Protection Program loan, which was pending SBA review after lender approval of forgiveness. Total long-term debt and other long-term obligations were $23.9 million.
- The revolving facility was extended to October 1, 2022, with up to $15.0 million available and an option to request an additional $5.0 million. The borrowing rate was 3.65% at December 31, 2020, and the facility was secured by substantially all assets.
- Total assets were $96.5 million and total equity was $46.9 million. Intangible assets, net, were $28.1 million, and contingent consideration related to Vibativ was $8.2 million.
Material changes versus the prior comparable period
- Revenue growth was driven principally by Kristalose, up 20.7%, and Vibativ, up 25.1%. RediTrex contributed $0.9 million following its late-2020 soft launch.
- Acetadote revenue declined $2.0 million, primarily because of lower Authorized Generic volume. Omeclamox-Pak revenue declined $0.6 million.
- Caldolor revenue increased modestly to $5.3 million, as higher international shipments offset lower U.S. demand caused by postponed elective procedures.
- Cost of products sold increased as a percentage of revenue to 23.1% from 21.6%, partly reflecting the product mix and Vibativ inventory accounting.
- Selling and marketing expense declined $0.5 million, and research and development expense declined $1.1 million as clinical activity slowed during the pandemic. Amortization increased $0.3 million.
- Operating cash flow improved to $5.4 million, but cash declined $3.5 million after investing and financing uses, including $1.9 million of share repurchases, $3.5 million of net debt repayment and $0.8 million used to repurchase CET shares.
- Ethyol and Totect were returned to Clinigen effective January 1, 2020 and are reported as discontinued operations. The company recorded $3.2 million of discontinued-operations income in 2020, including $3.0 million of installment consideration from Clinigen.
- The company repurchased 503,626 common shares for approximately $1.8 million during 2020. Approximately $6.2 million remained available under the repurchase authorization at year-end.
Guidance, outlook, management commentary, risks and unusual items
The filing does not provide formal quantitative revenue, earnings or cash-flow guidance. Management expects RediTrex to receive a broader national launch in the second half of 2021 once product supplies and market conditions normalize, and expects Caldolor demand to improve as elective procedures resume.
- COVID-19 reduced hospital admissions, elective surgeries, physician visits and access to clinical sites. It negatively affected Caldolor, Omeclamox-Pak and certain clinical programs, although Vibativ and Vaprisol benefited from increased hospital demand in some settings.
- Omeclamox-Pak packaging operations were suspended after the packager encountered financial difficulties. Cumberland notified the FDA of a shortage effective October 14, 2020 and had not provided a new inventory availability date.
- Clinical enrollment for Phase II ifetroban programs in DMD, systemic sclerosis and AERD slowed or was interrupted during the pandemic. These candidates remain unapproved and may not be successfully commercialized.
- Key risks include dependence on third-party manufacturers and distributors, concentration of customers, generic competition, patent challenges, reimbursement and pricing pressure, regulatory compliance, product liability and possible impairment of intangible assets.
- Three customers each represented at least 10% of 2020 revenue and together accounted for 71%; accounts receivable from customers representing at least 10% of revenue were 60% of total accounts receivable at year-end.
- The company remained in compliance with its tangible capital ratio covenant at December 31, 2020. Failure to maintain debt covenants could permit acceleration of borrowings or termination of lending commitments.
- Acetadote patents extend into 2025-2026, but the company continues to face generic challenges. Caldolor’s earliest cited patent expires in November 2021, with additional patents extending later.
- The company reported effective disclosure controls and effective internal control over financial reporting under management’s assessment. The independent auditor expressed an unqualified opinion on the financial statements but was not engaged to audit internal control effectiveness.
Most important facts for investors to verify
- Whether revenue growth from Kristalose and Vibativ can offset declines in Acetadote and the supply interruption affecting Omeclamox-Pak.
- The timing and commercial traction of the RediTrex national launch and the recovery of Caldolor demand after COVID-19 disruptions.
- The status of SBA forgiveness for the $2.2 million PPP loan and the company’s remaining borrowing capacity and covenant compliance.
- The sustainability of positive operating cash flow excluding the $3.5 million contribution from discontinued operations.
- Potential inventory obsolescence, intangible-asset impairment and the realization of approximately $22.3 million of total inventory, including $11.7 million classified as non-current.
- Progress, enrollment and eventual regulatory prospects for the Phase II ifetroban programs.
- Customer and supplier concentration, generic-entry timing, patent litigation developments and the resolution of the Omeclamox-Pak packaging shortage.